Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Ankylosing Spondylitis Clinical Trial

Official title:

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05861102
• Other study ID #: ZGJAK029
• Status: Recruiting
• Phase: Phase 3
• Start date: July 20, 2023
• Est. completion date: July 2025

Study information

• Verified date: July 2023
• Source: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Contact: Bin Xie
• Phone: +86-0512-57018310
• Email: xieb[@]zelgen.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).

Description:

Approximately 258 eligible subjects (129 per arm) will be randomized in a 1:1 ratio to Jaktinib 100mg BID (twice daily) or matching placebo BID for a total of 16 weeks of blinded treatment. During the 16-week treatment period subjects will visit the clinic every two weeks until the Week 4 visit and then every 4 weeks until the completion of Week 16.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 258
• Est. completion date: July 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Participants must be able to understand the study and signed the informed consent.

• 18-65 years, male or female.

• Participants with a clinical diagnosis of ankylosing spondylitis (AS), and radiologic evidence (x-ray) fulfilling the Modified New York criteria for AS(1984).

• Participants must have baseline disease activity as defined by having a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score = 4 and a Patient's Assessment of Total Back Pain score = 4 based on a 0 - 10 Numeric Rating Scale (NRS) at the Screening and Baseline Visits.

• Participants may be receiving the following Disease-Modifying Anti-Rheumatic Drugs(DMARDs) at the time of the screening visit. These medications should be continued throughout the entire study and doses should remain unchanged.

• Participants has had an inadequate response to at least two Nonsteroidal Anti-inflammatory Drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for NSAIDs.

• Participants who are regularly taking NSAIDs (including COX-1 or COX-2 inhibitors) as part of their AS therapy are required to be on a stable dose for at least 2 weeks before randomisation.

• Participants receiving non-prohibited concomitant medications for any reason must be willing to stay on a stable regimen as defined in the protocol.

Exclusion Criteria:

• History of known or suspected complete ankylosis of the spine.

• Any subject with condition affecting oral drug absorption.

• Participants taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine) within 4 weeks before randomization.

• Participants on any other DMARDs within 4 weeks or five half-lives (whichever is longer) of the drug prior to the Baseline visit.

• Participants has a history of inflammatory arthritis of different etiology other than axial SpA (including but not limited to rheumatoid arthritis, mixed connective tissue disease, systemic lupus erythematosus, reactive arthritis, scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset prior to 17 years of age.

• Significant trauma or surgery procedure within 8 weeks prior to randomization, or any planned elective surgery during the study period.

• Participants with a known immunodeficiency disorder or a first degree relative with a hereditary immunodeficiency.

• Participants with any condition possibly affecting oral drug absorption, eg, gastrectomy, clinically significant diabetic gastroenteropathy, or certain types of bariatric surgery.

• Use of any investigational drug and/or devices within 4 weeks of randomization or a period of 5 half-lives of the investigational drug, whichever is longer.

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Spondylarthritis
• Spondylitis
• Spondylitis, Ankylosing

Intervention

Drug:
• Jaktinib
Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
• Placebo
Participants will receive matching placebo orally twice daily for 16 weeks

Locations

Country	Name	City	State
China	RenJi Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants with Assessment in Ankylosing Spondylitis (ASAS) 40 response at Week 16	ASAS40 is defined as a >= 40% improvement and an absolute improvement of = 2 units (on a scale of 0 to 10) from Baseline in at least 3 of the 4 domains (patient's global assessment, back pain, function and inflammation) with no worsening at all in the remaining domain.	Week 16
Secondary	Percentage of Participants with Assessment in Ankylosing Spondylitis (ASAS) 20 response at Week 16.	ASAS20 is defined as a >= 20% improvement and an absolute improvement of >= 1 units (on a scale of 0 to 10) from Baseline in at least 3 of the 4 domains (patient's global assessment, back pain, function and inflammation) with no deterioration in the remaining domain (where deterioration is defined as a worsening of >= 20% and a net worsening of >= 1 unit [on a scale of 0 to 10])	Week 16
Secondary	Percentage of Participants with Assessment in Ankylosing Spondylitis (ASAS) 40 response at Week 2?4?8 and 12.	ASAS40 is defined as a >= 40% improvement and an absolute improvement of = 2 units (on a scale of 0 to 10) from Baseline in at least 3 of the 4 domains (patient's global assessment, back pain, function and inflammation) with no worsening at all in the remaining domain.	Week 2?4?8 and 12
Secondary	Percentage of Participants with Assessment in Ankylosing Spondylitis (ASAS) 20 response at Week 2?4?8 and 12.	ASAS20 is defined as a >= 20% improvement and an absolute improvement of >= 1 units (on a scale of 0 to 10) from Baseline in at least 3 of the 4 domains (patient's global assessment, back pain, function and inflammation) with no deterioration in the remaining domain (where deterioration is defined as a worsening of >= 20% and a net worsening of >= 1 unit [on a scale of 0 to 10])	Week 2?4?8 and 12